Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azyter is a preservative-free ophthalmic solution containing 1.5% azithromycin, a macrolide antibiotic of the azalide subclass. Developed by Laboratoires Théa, it is specifically indicated for the treatment of purulent bacterial conjunctivitis and trachomatous conjunctivitis caused by *Chlamydia trachomatis*. The formulation utilizes a medium-chain triglyceride vehicle that enhances the residence time of the active ingredient on the ocular surface, allowing for a simplified and shortened dosing regimen of one drop twice daily for three days. Azithromycin works by binding to the 50S subunit of the bacterial ribosome, which inhibits RNA-dependent protein synthesis and prevents the growth of susceptible bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azyter (azithromycin).